WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 23, 1077-1094. Research Article ISSN 2277–7105

CAR-T CELL THERAPY: NEW APPROACHES FOR THETREATMENT OF CANCER

Tanishq Gupta[1]*, Rishabh Kashiya[2] and Varsha Gupta[3]

Nutanben Mansukhbhai Turakhia Gujarati College of Pharmacy Scheme 54 PU4, Indore (452010), India.

Article Received on
14 October 2024,

Revised on 03 Nov. 2024,
Accepted on 24 Nov. 2024

DOI: 10.20959/wjpr202423-34794

***Corresponding Author**
Tanishq Gupta
Nutanben Mansukhbhai Turakhia Gujarati College of Pharmacy Scheme 54 PU4, Indore (452010), India.

ABSTRACT

Utilizing the immune system to precisely target and eradicate cancerous cells, chimeric antigen receptor (CAR) T cell therapy is a major breakthrough in the treatment of cancer (Sterner & Sterner, 2021). The development of CAR T cell therapy is reviewed here, covering its processes and progression from first-generation CARs to more sophisticated versions, such as second, third, and fourth-generation CARs, also referred to as TRUCKs (T-cells Redirected for Antigen- unrestricted Cytokinin-initiated Killing) (Mohanty et al., 2019). To increase T cell activation, durability, and efficacy—particularly in overcoming the obstacles presented by solid tumors—each generation integrates improved co-stimulatory domains and inducible cytokine production (Holzinger & Abken, 2022c). With precision targeting and long-lasting responses, CAR T cell therapy has shown exceptional efficacy in treating hematologic malignancies, including B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022). Significant obstacles still need to be overcome, though, such as manufacturing and logistical difficulties that prevent widespread accessibility and serious side effects include immunological effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) (Baker et al., 2023). Continuous research endeavors to address these unfavorable outcomes, optimize manufacturing procedures, and broaden the scope of CAR T cell therapy's use to a more extensive array of malignancies, encompassing solid tumors (Sharpe & Mount, 2015). Future developments are anticipated to improve CAR T cell therapy's efficacy, safety, and cost-effectiveness while also providing patients with relapsed or refractory tumors with new hope

(Majumder, 2023). This study highlights the promise of CAR T cell therapy to transform cancer treatment by providing a thorough analysis of its current state, clinical applications, advantages, difficulties, and future prospects.

KEYWORDS: Chimeric Antigen Receptor (CAR) T cell therapy, Oncology, Immunotherapy, Hematologic malignancies, Solid tumors, TRUCKs, Genetic engineering, Tumor microenvironment, Antigen escape, T cell persistence.

INTRODUCTION

Chimeric antigen receptor-engineered T cells, or CAR-T cells, are specifically designed to reroute immune effector cells (Mohanty et al., 2019). Recombinant 1-polypeptide chain transmembrane receptors, or CARs, are molecules that help recognize targets and activate cells (Holzinger & Abken, 2022c). When a cognate antigen is engaged, CAR harnesses the TCR's downstream signaling machinery to trigger T-cell activation (Baker et al., 2023). The major signal (signal-1) is carried by the first gene of CARs, and the T-cell co-stimulation domain (signal-2) is combined with the second gene (Sterner & Sterner, 2021). For T-cell activation to be complete and durable, both signals must exist (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022). In the terminal maturation stage, third-generation CARs outperform T-cells by combining with the T-cell co-stimulation domain (Majumder, 2023). Redirected for Antigen- unrestricted Cytokinin-initiated Killing (TRUCKs) is the name given to CAR T-cells that have been genetically modified to include an extra transgenic "payload" (Marco et al., 2023).

Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary approach to cancer treatment that targets and eliminates cancerous cells specifically using the body's immune system (Mohanty et al., 2019). This novel method entails genetically modifying a patient's T cells to produce CARs, which bind to antigens on the surface of cancer cells and cause them to be destroyed (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022). CAR T cell treatment has proven to be effective in a number of clinical contexts, with hematologic malignancies showing particular promise (Holzinger & Abken, 2022).

Modification of T cells to increase their durability and function is an essential component of CAR T cell therapy (Sterner & Sterner, 2021). Co-stimulatory domains that enhance T cell activation and proliferation upon exposure to their target antigen have been added to second and third generation CARs (Sharpe & Mount, 2015). These changes have increased the

length of remission and decreased the rate of relapse, which has greatly enhanced the therapeutic results (Mohanty et al., 2019).

Notwithstanding its achievements, CAR T cell treatment has a number of drawbacks and obstacles that need for continued study and advancement (Baker et al., 2023). Managing serious side effects like neurotoxicity and cytokine release syndrome (CRS), which can be fatal if left unchecked, is one of the biggest challenges (Majumder, 2023). Researchers are working hard to find ways to lessen these side effects, such as using more effective CAR designs that decrease off-tumor activity and targeted therapy (Holzinger & Abken, 2022).

A further major barrier to the widespread use of CAR T cell therapy is production and logistical concerns (Sterner & Sterner, 2021). The time-consuming and expensive nature of the T cell collection, engineering, and expansion procedure prevents this treatment from being available to a larger number of patients (Sharpe & Mount, 2015). To increase efficiency and lower costs, novel approaches to manufacture are being investigated (Majumder, 2023). One such approach isthe creation of commercially available CAR T cells that are sourced from allogeneic donors (Baker et al., 2023).

 # TYPES OF CARs

Over multiple generations, Chimeric Antigen Receptors (CARs) have been developed with the goal of improving the safety and effectiveness of CAR T-cell therapy (Mohanty et al., 2019). An outline of the many CAR kinds is provided below:

A. The 1st generation of CARs

Organization: The sole signaling domain that makes up these CARs is derived from the CD3ζ chain (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022).

Function: The T cell attacks the cancer cell after receiving an activation signal from the CAR through the CD3ζ chain (Sterner & Sterner, 2021).

Limitations: Due to insufficient T cell activation and persistence, first-generation CARs showed limited clinical efficacy despite their success in pre-clinical trials (Mohanty et al., 2019).

B. CARs of Second Generation

Structure: The CD3ζ signaling domain plus an extra co-stimulatory domain, usually from CD28 or 4-1BB (CD137), are both present in these CARs (Holzinger & Abken, 2022c).

Function: The addition of a co-stimulatory domain improves anti-tumor responses by increasing T cell activation, proliferation, and persistence (Sharpe & Mount, 2015).

Clinical Impact: Patients with recurrent B-cell acute lymphoblastic leukemia (B-ALL) have demonstrated remarkable responses to second-generation CARs, with some seeing complete remission rates of up to 90% (Mohanty et al., 2019).

C. CARs of the Third Generation

Structure: These CARs have the CD3ζ signaling domain in addition to two co-stimulatory domains (e.g., CD28 and 4-1BB) (Holzinger & Abken, 2022).

Function: T cell activation, proliferation, cytokine generation, and overall anti-tumor activity are all further enhanced by the twin co-stimulatory domains (Marco et al., 2023).

Examples: Patients with chronic lymphocytic leukemia (CLL) have shown high rates of complete remission while using a third-generation CAR made up of α-CD19-CD3η-CD28-4-1BB (Baker et al., 2023).

D. T cells redirected for universal cytokine killing, or TRUCKs, are fourth-generation CARs

Organization: By including cytokine or other immune-modulating agent inducible expression, like IL-12, these CARs improve upon the third-generation architecture (Majumder, 2023).

Function: By boosting T cell activation and overcoming immune suppression within the tumor, the addition of cytokine synthesis aids in the modulation of the tumor microenvironment (Mohanty et al., 2019).

Benefits: Fourth-generation CARs are designed to increase efficacy against solid tumors, which are more difficult to treat since they are immunosuppressive and diverse (Holzinger & Abken, 2022).



Figure 1: Trucks, The Fourth Generation.

With each new generation of CARs, certain issues from previous iterations have been addressed, resulting in ever-improving CAR T-cell treatment results (Sterner & Sterner, 2021). The ongoing attempts to enhance the accuracy, effectiveness, and safety of this innovative cancer treatment are reflected in the design of CARs, which is always evolving (Majumder, 2023).



Figure 2: Generations of Car-T Cells.

TYPES OF CANCER TREATED BY CAR-T CELL THERAPY

1. B-Cell acute lymphoblastic leukemia (Mohanty et al., 2019).
2. Certain b-cell lymphoma (Holzinger & Abken, 2022).

3. Mantle cell lymphoma (Sharpe & Mount, 2015).
4. Multiple myeloma (Sterner & Sterner, 2021).
5. Follicular lymphoma (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022).

BENEFITS OF CAR-T CELL THERAPY

1. **Precise Targeting:** CAR-T cell treatment provides extremely accurate cancer cell targeting. It guarantees that the immune system can precisely identify and target cancerous cells while preserving healthy tissues by genetically modifying T cells to express chimeric antigen receptors (CARs), which are receptors for certain antigens on the surface of cancer cells. This accuracy raises the treatment's overall safety and effectiveness while lowering off-target effects (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022).

2. **Potential for Long-lasting Responses:** The ability of CAR-T cell therapy to produce long-lasting responses is one of its many amazing advantages. After the patient receives the infusion, the CAR-T cells can live and function in the body for a considerable amount of time. In contrast to conventional treatments, this persistence enables ongoing monitoring and elimination of cancer cells, resulting in a prolonged remission and a decreased risk of recurrence (Baker et al., 2023).

3. **Alternative Therapy Option:** For patients who have not responded to traditional treatments including radiation and chemotherapy, CAR-T cell therapy is a useful substitute. For people with hematologic malignancies such as B-cell acute lymphoblastic leukemia and some forms of lymphomas, where other therapy may have failed, it gives hope for those with refractory or relapsed tumors (Shah et al., 2021).

4. **Minimal Residual Disease:** The little amount of cancer cells that remain in the body after treatment and might cause relapse is known as minimal residual disease (MRD), and CAR-T cell therapy has demonstrated efficacy in eradicating MRD. CAR-T cells have the ability to specifically target these remaining cells, resulting in deeper remissions and a lower risk of disease recurrence (Mohanty et al., 2019).

5. **Single Treatment Approach:** CAR-T cell therapy frequently requires a single administration, in contrast to many cancer medicines that necessitate many treatment

cycles. After the initial infusion of CAR-T cells, the modified T cells proliferate and maintain their anti-cancer activity, potentially reducing the need for ongoing treatment and minimizing the burden on patients (Holzinger & Abken, 2022).

6. **Personalized Medicine:** One type of personalized medicine that is catered to eachpatient specifically is CAR-T cell therapy. The procedure is obtaining the patient's own Tcells, transforming them genetically to produce CARs, and then injecting the patient with the modified cells. By providing a tailored therapy based on the patient's particular cancer profile, this personalized method improves the specificity and efficacy of the treatment (Sharpe & Mount, 2015).

7. **Prospect for Solid Tumors:** CAR-T cell therapy has shown promise in treating hematologic malignancies, but it may also be applied to solid tumors in the future. Expanding the use of CAR-T cell therapy, advances in CAR design are being investigated to overcome the obstacles presented by the tumor microenvironment in solid tumors. These include the insertion of extra co-stimulatory signals and cytokine expression (Sterner & Sterner, 2021).

8. **Survival Rate:** Impressive survival rates for patients receiving CAR-T cell therapy have been shown in clinical trials and real-world investigations; some patients even achieve complete remission. CAR-T cell treatment has been shown to increase survival rates for some tumors from 40% to 60% when compared to standard medicines. This is especially true for patients who have few other options. These results demonstrate the potential of CAR-T cell treatment to provide cancer patients with significant and long-lasting benefits (Marco et al., 2023).

SIDE EFFECTS OF CAR-T CELL THERAPY

CAR T-cell therapy, while effective, can cause severe side effects, including cytokine release syndrome (CRS) and neurologic effects, known as immune effector cell–associated neurotoxicitysyndrome (ICANS).

1. **Cytokine Release Syndrome (CRS):** A number of grave symptoms can arise from the excessive release of cytokines by infused CAR T cells. High fevers, sharp dips in blood pressure, and in the worst situations, lethal results are the symptoms (Majumder, 2023). Management: Standard supportive medications, such as steroids, can be used to treat mild cases of CRS. In severe situations, tocilizumab (Actemra), a cytokine that is substantially

implicated, is often used to prevent its activity (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022).

2. **Neurologic consequences (ICANS):** Speech impairment, extreme disorientation, and seizure-like behavior are some of these adverse consequences. The precise etiology of ICANS remains unclear. Seizures, cognitive abnormalities, and difficulties speaking are the symptoms (Baker et al., 2023). Management: Tocilizumab is ineffective for ICANS, in contrast to CRS. Severe cases are treated with steroids, especially dexamethasone, which more efficiently enters the central nervous system (Sharpe & Mount, 2015).

Understanding and managing these side effects are crucial for the safe and effective use of CAR T-cell therapies (Holzinger & Abken, 2022).

 # THE PROCESS OF CAR-T CELL THERAPY

A thorough explanation of the CAR T-Cell Cancer Therapy procedure, an immunotherapy used to treat specific cancers. The complete procedure takes about four to five weeks and includes the following crucial steps:

1. **Leukapheresis:** The patient's T-cells, a subset of white blood cells essential to the immunological response, are collected as the first stage. During a process known as leukapheresis, blood is collected from the patient and T-cells are separated from the other blood components. The patient receives the remainder of the blood (Marco et al., 2023).

2. **Reprogramming:** Next, in a lab setting, the extracted T-cells undergo genetic reprogramming. This entails using a lentiviral vector to introduce a genetic sequence that allows the T-cells to create chimeric antigen receptors (CARs) on their surface. T-cells are able to identify and adhere to particular proteins on the surface of cancer cells thanks to synthetic proteins called CARs (Sterner & Sterner, 2021).

3. **Generation of CAR T-Cells:** After being reprogrammed, the altered T-cells—now known as CAR T-cells—are able to identify and attach to markers of cancer cells. This identification is essential because it sets off the CAR T-cells, which attack and eradicate the cancer cells (Holzinger & Abken, 2022).

4. **Expansion:** Following a successful reprogramming, millions of identical copies of the CAR T-cells are grown in a laboratory. When the patient is reintroduced, this amplification guarantees that there are sufficient CAR T-cells to efficiently target and

eliminate cancer cells (Shah et al., 2021).

5. **Conditioning:** The patient goes through a conditioning regimen, usually consisting of chemotherapy, prior to receiving the expanded CAR T-cells again. By taking this action, the patient's body is better prepared to support the proliferation and efficient operation of CAR T-cells (Majumder, 2023).

6. **Administration:** An infusion is used to reintroduce the enlarged and reprogrammed CAR T-cells to the patient. The patient's bloodstream is circulated by these CAR T-cells, which locate and eliminate cancer cells (Baker et al., 2023).

7. **Monitoring:** The patient is continuously watched to control any side effects and evaluate the efficacy of the therapy following infusion. Monitoring is essential to guarantee the patient's safety and response to the treatment, as well as to identify any possible adverse events, such as neurological toxicity or cytokine release syndrome (CRS) (Mohanty et al., 2019).

This extensive procedure is a major breakthrough in individualized cancer treatment since it makes use of the patient's own immune cells, strengthening them to fight cancer (Marco et al., 2023).



Figure 3: The Process of CAR-T Cell Therapy.

ATTACKING PROCESS OF CAR-T CELL

The Making of a CAR T-Cell Attack

1. **Inactive Virus:** An inactive virus acts as a vector to transfer particular genetic material into T cells at the start of the procedure. The gene encoding the Chimeric Antigen Receptor (CAR) is present in this altered virus (Sterner & Sterner, 2021).

2. **T Cell:** From the patient's blood, a T cell is separated. T cells are an essential part of the immune system that recognize and combat diseased or malignant cells (Sharpe & Mount, 2015).

3. **Virus Insertion into T Cell:** The CAR gene-containing inactive virus is introduced into the T cell. Transduction is the process by which the viral vector incorporates the CAR gene into the DNA of the T cell (Holzinger & Abken, 2022).

4. **Creation of the Chimeric Antigen Receptor (CAR):** After the CAR gene is expressed within the T cell, the Chimeric Antigen Receptor is produced on the cell surface. By focusing on antigens specific to cancer cells, the CAR helps T cells identify these cells with precision (Mohanty et al., 2019).

5. **The CAR T Cell Adheres to and Targets the Cancer Cell:** The patient receives a second injection of the modified CAR T cell, which now has the CAR on its surface. The T cell is able to selectively attach to antigens on the surface of the cancer cell thanks to the CAR. The T cell attacks the cancer cell as a result of this binding (CAR T Cells: Engineering Immune Cells to Treat Cancer, 2022).

6. **Cancer Cell Dies:** The CAR T cell destroys the cancer cell by activating its cytotoxic capabilities after attaching to it. Through this procedure, the cancer cell dies, thereby lessening the patient's tumor burden (Baker et al., 2023).

These graphic highlights the novel strategy and mode of action of CAR T-cell treatment by skillfully illustrating the transition from a normal T cell to an engineered CAR T cell capable of accurately targeting and killing cancer cells.



Figure 4: The Making of a CAR T-cell Therapy Attack.

CLINICAL APPLICATIONS OF CAR-T CELL THERAPY

Table 1: Clinical Applications.

Generic Name	Brand Name	Target Antigen	TargetedDisease	Patient Population
Tisagenlecleucel	Kymriah	CD19	B-cell acute lymphoblastic leukemia (ALL) & B-cell non-Hodgkin lymphoma (NHL)	Children & young adultswith refractory or relapsed B-cell ALL and Adultswith relapsed or refractory B-cell NHL. (Shah et al.,2021)
Axicabtagene ciloleucel	Yescarta	CD19	B-cell non- Hodgkin lymphoma (NHL) & Follicular lymphoma	Adults with relapsed or refractory B-cell NHL. (Majumder, 2023)
Brexucabtagene autoleucel	Tecartus	CD19	Mantle cell lymphoma (MCL) & B-cell acute lymphoblastic leukemia (ALL)	Adults with relapsed or refractory B-cell MCL &ALL. (Sterner & Sterner,2021)
Lisocabtagene maraleucel	Breyanzi	CD19	B-cell non- Hodgkin lymphoma (NHL)	Adults with relapsed or refractory B-cell NHL. (Mohanty et al., 2019)
Idecabtagene vicleucel	Abecma	BCMA	Multiple myeloma	Adults with relapsed or refractory Multiple myeloma. (Holzinger & Abken,2022)
Ciltacabtagene autoleucel	Carvykti	BCMA	Multiple myeloma	Adults with relapsed or refractory multiple myeloma. (Marco et al., 2023)

CHALLENGES & LIMITATIONS IN CAR-T CELL THERAPY

1. **Antigen Escape:** The development of resistance in malignancies as a result of target antigen loss or downregulation poses a serious threat. Antigen escape is the mechanism that causes CAR-T cells to be unable to identify and target cancer cells. For example,

recurrence may occur in up to 70% of patients receiving CD19-targeted CAR-T treatment for acute lymphoblastic leukemia (ALL) as a result of losing CD19 expression (Shah et al., 2021).

2. **Toxicity:** Cytokine release syndrome (CRS) and neurotoxicity are two serious adverse effects of CAR-T cell treatment. These toxicities, which require careful control and result in serious clinical problems, are the consequence of the strong immunological response that CAR-T cells have produced (Sterner & Sterner, 2021).

3. **Limited Effectiveness in Solid Tumors:** Although CAR-T cell therapy has demonstrated impressive results in hematological malignancies, its potential for treating solid tumors is still restricted. This problem is exacerbated by elements like the tumor microenvironment, physical obstacles to CAR-T cell penetration, and variable antigen expression (Baker et al., 2023).

4. **Durability and Persistence:** Another difficulty is ensuring the CAR-T cells in patients survive over the long term. CAR-T cells must continue to multiply and remain active over time in order to provide sustained remission; however, co-stimulatory domains and the immune system can have an impact on how long they live (Holzinger & Abken, 2022).

5. **Manufacturing Complexities:** The process of creating CAR-T cells is costly, time-consuming, and complex. For widespread therapeutic application, there are logistical and cost obstacles because each patient's cells must be individually changed and amplified (Sharpe & Mount, 2015).

Addressing these limitations requires ongoing research into multi-antigen targeting strategies, improved safety management protocols, advancements in CAR-T cell design, and streamlined manufacturing processes. These efforts aim to enhance the efficacy, safety, and accessibility of CAR-T cell therapies in both hematologic and solid tumors (Marco et al., 2023).

FUTURE OUTLOOKS OF CAR-T CELL THERAPY

1. **Growing Indications:** Clinical trials are investigating the effectiveness of CAR T therapy in tumors like glioblastoma, sarcoma, breast cancer, and pancreatic cancer, providing patients with cancers that have historically been difficult to treat with hope

(Majumder, 2023).

2. **Improving Safety Profile:** Researchers want to make it more tolerable, apply it to a wider range of patients, improve its safety features, and create plans to deal with side effects (Mohanty et al., 2019).

3. **Improving Efficacy:** Researchers want to raise the proportion of patients who have a long-term reduction in symptoms, enhance T cell function, and defeat immune evasion strategies used by cancer cells (Sterner & Sterner, 2021).

4. **Cutting expenses & Increasing Accessibility:** Research endeavors were directed on streamlining production procedures, lowering expenses, and keeping an eye on market safety (Baker et al., 2023).

CONCLUSION

CAR-T cell therapy represents a significant advancement in the field of oncology, leveraging the body's immune system to combat cancer with high precision and efficacy. This therapy has evolved through successive generations, incorporating enhanced co-stimulatory domains and inducible cytokine production to improve T cell activation, persistence, and overall therapeutic outcomes. Notably, CAR-T cell therapy has achieved remarkable success in treating hematologic malignancies such as B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma, offering hope to patients with relapsed or refractory diseases.

Despite these achievements, CAR-T cell therapy faces several challenges, including severe side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and logistical issues related to the manufacturing and distribution of the therapy. Moreover, its application to solid tumors remains limited due to the complex tumor microenvironment and issues of antigen escape.

Future research is focused on overcoming these hurdles by optimizing CAR designs, improving safety profiles, enhancing the manufacturing process, and expanding the therapy's applicabilityto a broader range of cancers, including solid tumors. Innovations such as TRUCKs and other advanced CAR constructs are being explored to enhance the efficacy against solid tumors and improve overall treatment outcomes.

In conclusion, CAR-T cell therapy holds transformative potential for cancer treatment, offering precise targeting, durable responses, and new therapeutic options for patients who have exhausted traditional treatments. Continued advancements in this field are expected to enhance the safety, efficacy, and accessibility of CAR-T cell therapy, bringing new hope to cancer patients worldwide. The ongoing evolution of CAR-T cell therapy promises to reshape the landscape of cancer treatment, providing a beacon of hope for many patients battling this formidable disease.

REFERENCES

1. CAR T Cells: Engineering Immune Cells to Treat Cancer. (2022, March 10). Cancer.gov. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
2. Holzinger, A., & Abken, H. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells. Pharmacology, 2022c; 107(9–10): 446–463. https://doi.org/10.1159/000525052
3. Wisnia, S. (2023d, December 8). Multiple Myeloma Patient Shines Bright as CAR T-Cell Therapy Outpatient. Dana-Farber Cancer Institute. https://blog.dana-farber.org/insight/2023/12/multiple-myeloma-patient-shines-bright-as-car-t-cell-therapy-outpatient/
4. Mohanty, R., Chowdhury, C., Arega, S., Sen, P., Ganguly, P., & Ganguly, N. (2019, September 24). CAR T cell therapy: A new era for cancer treatment (Review). Oncology Reports. https://doi.org/10.3892/or.2019.7335
5. Sterner, R. C., & Sterner, R. M. (2021, April 6). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal. https://doi.org/10.1038/s41408-021-00459-7
6. Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023, July 26). CAR T therapy beyond cancer: the evolution of a living drug. Nature. https://doi.org/10.1038/s41586-023-06243-w
7. Marco, R. C. D., Monzo, H. J., & Ojala, P. M. (2023, March 27). CAR T Cell Therapy: A Versatile Living Drug. PubMed Central. Retrieved March 8, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094630/
8. Sharpe, M., & Mount, N. (2015, April 1). Genetically modified T cells in cancer therapy: opportunities and challenges. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.018036
9. Majumder A. Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific

Discovery to Cures (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777914/). Cancers (Basel), Dec. 20, 2023; 16(1): 39.

10. Shah NN, Lee DW, Yates B, et. al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL (https://pubmed.ncbi.nlm.nih.gov/33764809/) J Clin Oncol, May 20, 2021; 39(15): 1650-1659.
11. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N. Engl. J. Med.*, 2018; **378:** 439–448.
12. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. C. A. R. T cell immunotherapy for human cancer. *Science*, 2018; **359:** 1361–1365.
13. Srivastava, S. & Riddell, S. R. Engineering CAR-T cells: design concepts. *Trends Immunol*, 2015; **36:** 494–502.
14. Bach, M., Gollner, S., & Rech, J. The role of immune checkpoints in T cellexhaustion and tumor immunotherapy. *Frontiers in Immunology*, 2022; 13: 1034707. https://doi.org/10.3389/fimmu.2022.1034707
15. Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J. Immunol*, 2008; **180:** 4901–4909.
16. Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunol. Rev.*, 2014; **257:** 107– 126.
17. Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nat. Rev. Clin. Oncol*, 2020; **17:** 147–167.
18. Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood.*, 2015; **125:** 4017–4023.
19. Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J. Clin. Invest*, 2019; **129:** 2210–2221.
20. Zhang, H. et al. A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma. *Blood*, 2019; **134:** 3147–3147.
21. Lin, Q., Zhao, J., Song, Y. & Liu, D. Recent updates on CAR T clinical trials for multiple myeloma. *Mol. Cancer*, 2019; **18:** 154.
22. Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol, 2012; 12: 269–281. View Article : Google Scholar : PubMed/NCBI

23. Galluzzi L and Martin P: CARs on a highway with roadblocks. Oncoimmunology, 6: e13884862017. View Article : Google Scholar : PubMed/NCBI
24. Sharpe M and Mount N: Genetically modified T cells in cancer therapy: Opportunities and challenges. Dis Model Mech., 2015; 8: 337–350. View Article : Google Scholar : PubMed/NCBI
25. Mirzaei HR, Jamali A, Jafarzadeh L, Masoumi E, Alishah K, Fallah Mehrjardi K, Emami SAH, Noorbakhsh F, Till BG and Hadjati J: Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. J Cell Physiol, 2019; 234: 9207–9215. View Article : Google Scholar : PubMed/NCBI
26. Yang QY, Yang JD and Wang YS: Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Immunol Lett., 2017; 190: 201–205. View Article : Google Scholar : PubMed/NCBI
27. Brentjens R, Yeh R, Bernal Y, Riviere I and Sadelain M: Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther., 2010; 18: 666–668. ViewArticle : Google Scholar : PubMed/NCBI
28. Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther., 2015; 15: 1145–1154. View Article : Google Scholar : PubMed/NCBI
29. Yin H, Kauffman KJ and Anderson DG: Delivery technologies for genome editing. Nat Rev Drug Discov, 2017; 16: 387–399. View Article : Google Scholar : PubMed/NCBI
30. Kebriaei P: CAR T-cell therapies: Overcoming the challenges and new strategies. Clin Lymphoma Myeloma Leuk, 2017; 17(2): S74–S78. View Article : Google Scholar
31. Paietta E: Immunobiology of acute leukemia. In: Neoplastic diseases of the bloodSpringer; Cham., 2018; 237–279.
32. Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A and Doshi S: Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 targeted cancer immunotherapy: Clinical pharmacology and its implications. Clin Pharmacokinet, 2016; 55: 1271–1288. View Article : Google Scholar : PubMed/NCBI
33. Barbee MS, Ogunniyi A, Horvat TZ and Dang TO: Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother, 2015; 49: 907–937. View Article : Google Scholar : PubMed/NCBI
34. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V,

Molin D, Vassilakopoulos TP, et al: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncolm, 2017; 35: 2125–2132. View Article : Google Scholar : PubMed/NCBI

35. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. *Eur J Immunol*, Oct. 1996; 26(10): 2304–9. https://doi.org/10.1002/eji.1830261006
36. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. *Expert Opin Biol Ther*., 2015; 15(8): 1145–54. https://doi.org/10.1517/14712598.2015.1046430
37. Holzinger A, Abken H. Advances and challenges of CAR T cells in clinical trials. *Recent Results Cancer Res*., 2020; 214: 93–128. https://doi.org/10.1007/978-3-030-23765-3_3.
38. Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Recent advances in CAR-T cell engineering. *J Hematol Oncol*, Jul. 2, 2020; 13(1): 86.
39. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. *Cancer Res*., Apr. 1, 2012; 72(7): 1844–52.
40. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Redirecting gene-modifiedT cells toward various cancer types using tagged antibodies. *Clin Cancer Res*., Dec. 1, 2012; 18(23): 6436–45.
41. Schaft N. The landscape of CAR-T cell clinical trials against solid tumors-a comprehensive overview. *Cancers*, Sep. 9, 2020; 12(9): E2567. https://doi.org/10.3390/cancers12092567.
42. Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, The European Medicines Agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. *Oncologist*, Feb. 2020; 25(2): e321–7.
43. Jain MD, Bachmeier CA, Phuoc VH, Chavez JC. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. *Ther Clin Risk Manag*, May 31, 2018; 14: 1007–17.
44. Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. *Oncotarget*, Oct. 20, 2015; 6(32): 33961–71.
45. Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. *Science*, 2022; **378:** 853–858.
46. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen

receptor–modified T cells in chronic lymphoid leukemia. *N. Engl. J. Med.*, 2011; **365:** 725–733.

47. Ali, S. A. et al. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. *Blood*, 2016; **128:** 1688–1700.
48. Ellis, G. I., Sheppard, N. C. & Riley, J. L. Genetic engineering of T cells for immunotherapy. *Nat. Rev. Genet*, 2021; **22:** 427–447.
49. Aghajanian, H., Rurik, J. G. & Epstein, J. A. CAR-based therapies: opportunities for immuno-medicine beyond cancer. *Nat. Metab*, 2022; **4:** 163–169.
50. Baker, D. J. & June, C. H. CAR T therapy extends its reach to autoimmune diseases. *Cell.*, 2022; **185:** 4471–4473.
51. Beheshti, S. A., Shamsasenjan, K., Ahmadi, M. & Abbasi, B. CAR Treg: a new approach in the treatment of autoimmune diseases. *Int. Immunopharmacol*, 2022; **102:** 108409.
52. Kakarla, S. et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. *Mol. Ther.*, 2013; **21:** 1611–1620.